T1G3期膀胱癌的最佳管理 - Suppr | 超能文献

The optimal management of T1G3 bladder cancer.

作者信息

Emiliozzi Paolo, Pansadoro Alberto, Pansadoro Vito

机构信息

San Giovanni Hospital, Rome, Italy.

出版信息

BJU Int. 2008 Nov;102(9 Pt B):1265-73. doi: 10.1111/j.1464-410X.2008.07969.x.

DOI:10.1111/j.1464-410X.2008.07969.x

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The optimal management of T1G3 bladder cancer.T1G3期膀胱癌的最佳管理

BJU Int. 2008 Nov;102(9 Pt B):1265-73. doi: 10.1111/j.1464-410X.2008.07969.x.

2

The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?卡介苗治疗非肌层浸润性膀胱癌后复发的同步放化疗结果：是否总是需要立即进行膀胱切除术？

BJU Int. 2009 Jul;104(2):179-83. doi: 10.1111/j.1464-410X.2008.08299.x. Epub 2008 Dec 23.

3

T1G3: What to do?T1G3：该怎么办？

Arch Ital Urol Androl. 1996 Feb;68(1):5-7.

4

The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.肌层浸润性膀胱癌新辅助化疗及膀胱切除术的病例分析

J Urol. 2009 May;181(5):1994-7. doi: 10.1016/j.juro.2009.02.052. Epub 2009 Mar 14.

5

T1 and T2 bladder cancer: selecting optimal therapy.T1和T2期膀胱癌：选择最佳治疗方案。

Eur Urol. 1998;33 Suppl 4:16-7. doi: 10.1159/000052256.

6

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.根据日本登记膀胱癌患者的数据得出的Ta、T1期非肌层浸润性膀胱癌肿瘤复发的临床结果：日本泌尿外科学会1999 - 2001年报告

Int J Urol. 2009 Mar;16(3):279-86. doi: 10.1111/j.1442-2042.2008.02235.x. Epub 2009 Jan 20.

7

Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.泌尿外科肿瘤学中的艰难决策：膀胱高级别T1期移行细胞癌的管理

Urol Oncol. 2007 Jul-Aug;25(4):338-40. doi: 10.1016/j.urolonc.2007.05.002.

8

[Treatment and follow-up of superficial bladder cancer].[浅表性膀胱癌的治疗与随访]

Duodecim. 2002;118(9):903-9.

9

[Usefulness of radiotherapy in the treatment of infiltrating bladder cancer].

Arch Esp Urol. 1990;43 Suppl 2:165-84.

10

T1G3 bladder cancer--the case for TUR and BCG.T1G3期膀胱癌——经尿道切除术和卡介苗治疗的情况

Front Radiat Ther Oncol. 2002;36:147-50. doi: 10.1159/000061336.

引用本文的文献

1

Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.膀胱 pT1 乳头状癌的茎干侵犯与基底侵犯：改良的亚分期系统预测进展风险。

Histopathology. 2017 Sep;71(3):406-414. doi: 10.1111/his.13247. Epub 2017 Jun 27.

2

Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?对于接受卡介苗膀胱内免疫治疗的原发性膀胱T1G3尿路上皮癌患者，是否有可能停止随访？

World J Urol. 2017 Feb;35(2):237-243. doi: 10.1007/s00345-016-1856-9. Epub 2016 Jun 9.